🎉 #Gate Post# Hits 50,000 Followers!
✨ To celebrate this amazing milestone, we're giving back to our incredible community!
🎁 4 Lucky Winners Will Each Receive $10 Points!
Join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your congratulations in the comments!
End at 18:00, May 25 (UTC)
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.